Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver diseaseStefan Traussnigg, Michael Trauner, Harald Hofer et al.|Wiener klinische Wochenschrift|2020Cited by 41